A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
Study sponsor: Arcturus Therapeutics, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-06-01Estimated
Enrollment · participants9Estimated
Source updated2025-03-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.